Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth

Disclosure of Inside Information Pursuant to Article 17 of Regulation (EU) No. 596/2014

NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION MAY BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE REFER TO THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

Formycon plans to issue a public senior unsecured floating rate bond with target volume of EUR 50 million to support further company growth

Planegg-Martinsried, Germany, 17 June 2025 – The Management Board of Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) (“Company”) today resolved, with the approval of the Supervisory Board, to examine the possibility of issuing a public senior unsecured, floating rate corporate bond with a target volume of EUR 50 million (ISIN: NO0013586024 / WKN: A4DFJH) (the “Bond”) to support its ongoing growth strategy (the “Transaction”). The Transaction is being jointly arranged by IKB Deutsche Industriebank AG and Pareto Securities AS (together, the “Joint Lead Managers”).

The issuance is intended to be carried out as a public offering (“Offering”) in Germany, Luxembourg and Austria based on a securities prospectus (“Prospectus”) which is expected to be approved today by the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) and to be notified to the German Federal Financial Supervisory Authority (BaFin) and the Austrian Financial Market Authority (FMA). The public offering relates to bonds with a total nominal value of up to EUR 50 million. The Prospectus will be published on the websites of the Luxembourg Stock Exchange (www.luxse.com) and the Company (www.formycon.com) under the “Investor Relations” section. In addition to the public offering, the Joint Lead Managers also intend to place the Bond with institutional investors in Germany, Luxembourg and Austria, as well as in selected European and other countries, via a private placement.

The net proceeds will be used to finance the development and expansion of the Company’s biosimilar product portfolio as part of its corporate growth strategy.

Interested investors may submit their binding offers to purchase bonds during the offering period either through Deutsche Börse’s subscription functionality “DirectPlace” (from June 20 to June 30, 2025, 12:00 noon CEST) or via the Company’s website (www.formycon.com; from June 18 to June 27, 2025, 11:59 p.m. CEST), subject to an early closing of the subscription period.

The Bond, governed by Norwegian law, will have a term of four years. The minimum investment amount is EUR 1,000. The interest rate will be based on the three-month EURIBOR plus a margin ranging from 7.0% to 7.5% per annum. The final margin and total nominal amount of the Bond are expected to be determined and communicated on or around June 30, 2025 based on the subscription offers received. The Bond is intended to be included in the Open Market (Freiverkehr) of the Frankfurt Stock Exchange. Additionally, the Company will apply for the Bond to be admitted to trading on the Euronext ABM, a self-regulated marketplace operated by the Oslo Stock Exchange (Oslo Børs), within six (6) months following issuance.

The final decision on the Transaction will depend on market conditions and the outcome of discussions with potential investors. The Company will inform the capital markets and the public of any developments in line with legal requirements.

For further information, please contact:

Sabrina Müller
Director Investor Relations and Corporate Communications
Formycon AG
Fraunhoferstraße 15
82152 Planegg/Martinsried
Germany

phone +49 (0) 89 - 86 46 67 149 | fax + 49 (0) 89 - 86 46 67 110
Sabrina.Mueller@formycon.com // www.formycon.com

Important Notice

This publication may not be published, distributed or transmitted in the United States of America, Canada, Australia or Japan. It does not constitute an offer or solicitation of an offer to purchase or subscribe for any securities in the United States, Australia, Canada or Japan or in any jurisdiction in which such offer or solicitation would be unlawful.

This publication constitutes neither an offer to sell nor a solicitation to buy securities of the Company. A public offer of securities in Germany, Luxembourg and Austria is made solely based on the securities prospectus to be approved by the Commission de Surveillance du Secteur Financier (“CSSF”) and to be notified to the German Federal Financial Supervisory Authority (BaFin) and the Austrian Financial Market Authority (FMA). The approval of the securities prospectus by the CSSF should not be understood as an endorsement of the securities offered. The securities prospectus alone includes the information for investors required by law. The securities prospectus will be made available free of charge on the Company's website (https://www.formycon.com/investoren/anleihe-2025) in the "Investor Relations" section.

Investors are recommended to read the securities prospectus carefully before deciding to purchase or sell notes of the Company in order to fully understand the potential risks and rewards associated with the decision to invest in the securities and to make an investment decision only on the basis of all available information about the Company after consultation with their own lawyers, tax and/or financial advisors.

In the Member States of the European Economic Area other than Germany, Luxembourg and Austria, this publication is only addressed to persons who are "qualified investors" within the meaning of Article 2(e) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market ("Prospectus Regulation").

In the United Kingdom, this publication may only be distributed to, and is only directed at, persons who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation as that Regulation forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 and who are also (i) professional investors within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time ("Order"), or (ii) are high net worth companies falling within Article 49(2)(a) to (d) of the Order or other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “relevant persons”). The new securities will only be available to relevant persons and any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities will only be made to relevant persons. Any person who is not a relevant person must not act or rely on these materials or their contents.

This publication does not constitute an offer of securities for sale in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The securities may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. There will be no public offering of these securities in the United States.

Certain statements contained in this publication may constitute "forward-looking statements". These forward-looking statements are based on management's current views, expectations, assumptions and information. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties.

Due to various factors, actual future results, developments and events may differ materially from those described in these statements; neither the Company nor any other person assumes any responsibility for the accuracy of the opinions contained in this communication or the underlying assumptions. The Company assumes no obligation to update any forward-looking statements contained in this publication. In addition, it should be noted that all forward-looking statements speak only as of the date hereof and that neither the Company nor the Joint Lead Managers undertake any obligation to update any forward-looking statements or to conform them to actual events or developments, except as required by law.

THIS DOCUMENT IS NOT A PROSPECTUS BUT A PROMOTIONAL DOCUMENT; INVESTORS SHOULD SUBSCRIBE FOR OR PURCHASE THE SECURITIES REFERRED TO IN THIS PROMOTIONAL DOCUMENT SOLELY ON THE BASIS OF THE INFORMATION CONTAINED IN THE PROSPECTUS.